BRG 399
Alternative Names: BRG-399Latest Information Update: 28 May 2026
At a glance
- Originator Berg Pharma
- Developer BPG Bio
- Class Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Small molecules
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters; Ubiquitin protein ligase modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Haematological malignancies
- No development reported Solid tumours
Most Recent Events
- 28 May 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 06 Aug 2024 Preclinical trials in Cardiovascular disorders (Prevention) in USA (unspecified route) prior to August 2024 (BPG bio Pipeline, August 2024)
- 06 Aug 2024 The US FDA approves IND application for BRG 399 in Solid tumours and Haematological malignancies prior to August 2024 (BPG bio Pipeline, August 2024)